Investor Guide: Health & Biotech FY2023
Prescient Therapeutics (ASX: PTX) featured in the ‘Investor Guide for Health & Biotech’ by The...
Prescient Therapeutics (ASX: PTX) featured in the ‘Investor Guide for Health & Biotech’ by The...
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR...
There are many foundations and charities which aim to tackle health conditions through funding medical...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.